FierceMedicalDevices Names Fractyl Laboratories a “Fierce 15” Med Tech Company of 2015
WALTHAM, MA. – October 14, 2015 – Fractyl Laboratories, Inc. (Fractyl) today announced that FierceMedicalDevices has named the Company a 2015 Fierce 15 medical technology companies, designating Fractyl as one of the most promising private med tech companies in the industry.
“We’re honored to be recognized by FierceMedicalDevices for our innovative work in type 2 diabetes,” said Harith Rajagopalan, MD, PhD, Co-Founder and CEO of Fractyl. “Our treatment approach uses a non-invasive procedure to address the role of the gut and hormones in type 2 diabetes, and we were pleased to report some very intriguing results from our first-in-human study this year. We look forward to the coming year as we complete our first multi-center human clinical trials.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceMedicalDevices’ fourth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at http://www.fiercemedicaldevices.com/special-reports/2015-fierce-15.
An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, FierceMedicalDevices provides subscribers with an authoritative analysis of the day’s top stories. Every year, FierceMedicalDevices evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of the company’s technology, partnerships, venture backers and market position.
FierceMedicalDevices keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical devices and diagnostics. More than 90,000 top industry professionals rely on FierceMedicalDevices for an insider briefing on the day’s top stories. Signup is free at www.fiercemedicaldevices.com/sign-up.
About Fractyl and the Revita™ Duodenal Mucosal Resurfacing (DMR) System
Fractyl Laboratories, Inc., a private company based in Waltham, MA, was founded with the mission to change the treatment of type 2 diabetes. Fractyl has developed a minimally invasive, device-based, implant-free duodenal mucosal resurfacing procedure (Revita DMR) that directly addresses the intestinal hormonal impairment that contributes to insulin resistance and changes how the body absorbs and processes sugar. Fractyl is currently engaged in clinical trials designed to demonstrate that the Revita DMR procedure can dramatically improve glucose control and potentially reduce the need for additional medications in type 2 diabetes.
For more information, visit www.fractyl.com
, or www.RevitaTrial.com
. Revita is for investigational use only.
Corporate Contact: Lisa Davidson, Chief Financial Officer, Fractyl Laboratories Inc, email@example.com,+1.781.902.8804
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., firstname.lastname@example.org,+1.858.344.8091